Who
Rodney W. Lappe
Director
Company insider
Files Form 4 as: Director, Design Therapeutics; Director and 10% owner, Mirati Therapeutics.
In numbers
- Trades disclosed
- 21
- Buys
- 3
- Sells
- 0
- Bought
- $269K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 9 Sep 2014
- Last trade
- 9 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,993 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 1 Dec 2023filed 5 Dec 2023 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,186 at $0.00 | filing |
| 29 Sep 2023filed 2 Oct 2023 | DSGN Design TherapeuticsBiotechnology | SEC FORM 4 Bought | $49K21,000 at $2.35 | filing |
| 31 May 2023filed 2 Jun 2023 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 9 Dec 2022filed 12 Dec 2022 | DSGN Design TherapeuticsBiotechnology | SEC FORM 4 Bought | $119K15,000 at $7.96 | filing |
| 15 Jun 2022filed 16 Jun 2022 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 30 Mar 2021filed 1 Apr 2021 | DSGN Design TherapeuticsBiotechnology | SEC FORM 4 Bought | $100K5,000 at $20.00 | filing |
| 25 Mar 2021filed 29 Mar 2021 | DSGN Design Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 Jan 2019filed 22 Jan 2019 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 18 Jan 2018filed 22 Jan 2018 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 May 2017filed 19 May 2017 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 30 Mar 2017filed 3 Apr 2017 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 18 May 2016filed 19 May 2016 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 21 May 2015filed 22 May 2015 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 9 Sep 2014filed 11 Sep 2014 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 9 Sep 2014filed 11 Sep 2014 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.